Earnings growth forecast for next year: Passage Bio Corp (PASG)
Passage Bio, Inc. (PASG) is developing neurogenic therapy in collaboration with the University of Pennsylvania, accelerating global trials. The estimated growth in net earnings per share for the coming year reflects market expectations, with the indicator valued at 49.90. The company relies on future sales of pediatric brain medications, although the business is exposed to binary risks due to its narrow specialization in viral vectors.
PASG (Passage Bio): analytical breakdowns and indicator data
- share price and consensus valuation forecast:
- company stock exchange capitalization indicators:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Passage Bio, Inc.|PASG - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Passage Bio Inc.|PASG - Company Cumulative Debt|Debt to Book Value Passage Bio|PASG - Company Long-Term Loans and Borrowings|Company Short-Term Debts Passage Bio|Quick Liquidity passagebio.com
- earnings and market ratios statistics:
PASG - Company Profit|Projected Future Earnings Passage Bio, Inc.|PASG - Price to Earnings Ratio|Projected Price to Earnings Passage Bio Inc.|PASG - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Passage Bio|PASG - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Passage Bio|PASG - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months passagebio.com|PASG - Expected net earnings per share growth this year|Earnings growth forecast for next year Passage Bio, Inc.
Fundamental company analysis:Passage Bio, Inc.
This indicator serves as a filter for stress-testing positions by identifying the gap between current value and future returns. The metric measures the percentage change in the consensus earnings per share (EPS) forecast, updating data daily to eliminate market distortions. Analyzing the 12-month expected EPS growth chart is critical for Passage Bio, Inc. (PASG), as a potential monopoly in CNS gene therapy allows for the integration of ultra-high pricing into forecasts.
Competitor analysis for Passage Bio, Inc.
BIIB (Biogen Corp) - Earnings growth forecast for next year|NBIX - Net earnings per one share growth forecast for next year|Earnings growth forecast for next year RGC|AXSM - Expected net earnings per share growth next year|ACADIA Pharmaceuticals Inc. - Expected earnings per share growth for next year|Expected earnings per share trend next year XENE|Viking Pharma - Earnings growth forecast for next year|SUPN: Net earnings per share growth forecast for next year|CPRX: Earnings growth forecast for next year|DNLI - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Harmony Biosciences Holdings, Inc.|Expected net earnings per share growth next year Biohaven Ltd BHVN|Expected earnings per share growth for next year AMLX (Amylyx)|TRVI (Trevi Corp) - Expected earnings per share trend next year|Earnings growth forecast for next year PRAX (Praxis Precision Medicines)|Consensus forecast of earnings per share growth for next year anavex.com (AVXL)|CBLL - Net earnings per share growth forecast for next year|PRTA (Prothena Corporation plc) - Projected earnings per share growth rate for next year|ALEC: Earnings growth forecast for next year|Expected earnings per share growth for next year Annexon Biosciences Inc.|Expected earnings per share growth for next year OMER|neurogene.com (NGNE) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year AC Immune SA (ACIU)|VYGR: Net earnings per share change forecast for next year|Earnings growth forecast for next year NMRA (Neumora Therapeutics Inc)|Earnings growth forecast for next year Scilex Holding Company, Inc. SCLX|TVGN - Net earnings per share growth forecast for next year|Consensus forecast of earnings per share growth for next year Alpha Cognition ACOG|CGTX: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Inhibikase Therapeutics Inc IKT|Net earnings per share growth forecast for next year Cassava|Projected earnings per share growth rate for next year ASRT (Assertio Therapeutics)|Earnings growth forecast for next year COYA|VTGN - Expected net earnings per share growth next year|Ovid Therapeutics - Expected earnings per share growth for next year|Earnings growth forecast for next year Acumen Pharmaceuticals Inc. ABOS|CRVO - Net earnings per share growth forecast for next year|Expected earnings per share trend next year ATHE (Alterity Therapeutics)|clene.com (CLNN) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year PepGen (PEPG)|Net earnings per share growth forecast for next year Jupiter Neurosciences Inc|Relmada Therapeutics Inc - Net earnings per share change forecast for next year|Earnings growth forecast for next year ANVS|Earnings growth forecast for next year gracetx.com (GRCE)|Net earnings per share growth forecast for next year Firefly Neuroscience, Inc AIFF|Consensus forecast of earnings per share growth for next year ANEW Medical (KLTO)|NRSN - Net earnings per share growth forecast for next year|Consensus forecast of earnings per share growth for next year Reviva Pharmaceuticals Holdings Inc. RVPH|MTVA: Earnings growth forecast for next year|NeurAxis Inc (NRXS) - Earnings growth forecast for next year|HSDT (Helius Medical Technologies, Inc.) - Earnings growth forecast for next year|NEUP - Net earnings per one share growth forecast for next year|Earnings growth forecast for next year NERV|ATHA - Expected net earnings per share growth next year|Addex Therapeutics, Ltd. - Expected earnings per share growth for next year|Expected earnings per share trend next year ALZN|Cyclerion - Earnings growth forecast for next year|PTIX: Net earnings per share growth forecast for next year|KTTA: Earnings growth forecast for next year|CRGT - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Avenue Therapeutics, Inc|Expected net earnings per share growth next year BrainStorm Cell Therapeutics Inc. BCLI|Expected earnings per share growth for next year CARA (Cara Therapeutics, Inc.)|CHRO (chromocell.com) - Expected earnings per share trend next year|Earnings growth forecast for next year ELYM (Eliem Therapeutics Inc.)|Consensus forecast of earnings per share growth for next year Intra-Cellular Therapies Inc. (ITCI)|LBPH - Net earnings per share growth forecast for next year|MRNS (Marinus Pharma) - Projected earnings per share growth rate for next year|NKGN: Earnings growth forecast for next year|Expected earnings per share growth for next year neurobopharma.com|Expected earnings per share growth for next year SAGE|Synaptogenix Inc. (SNPX) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Trevena, Inc (TRVN)|VIGL: Net earnings per share change forecast for next year|Earnings growth forecast for next year WENA (Anew Medical)|Earnings growth forecast for next year cerevel.com CERE
